Moderate Pain - Pipeline Review, H1 2014

LONDON, June 12, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Moderate Pain - Pipeline Review, H1 2014

http://www.reportbuyer.com/pharma_healthcare/treatments/moderate_pain_pipeline_review_h1_2013.html

Moderate Pain - Pipeline Review, H1 2014

Summary

Global Markets Direct's, 'Moderate Pain - Pipeline Review, H1 2014', provides an overview of the Moderate Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Moderate Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Moderate Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Moderate Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Moderate Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Moderate Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Global Markets Direct Report Coverage 8
Moderate Pain Overview 9
Therapeutics Development 10
Pipeline Products for Moderate Pain - Overview 10
Pipeline Products for Moderate Pain - Comparative Analysis 11
Moderate Pain - Therapeutics under Development by Companies 12
Moderate Pain - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Moderate Pain - Products under Development by Companies 18
Moderate Pain - Companies Involved in Therapeutics Development 20
Nektar Therapeutics 20
Egalet Corporation 21
Laboratorios Del Dr. Esteve S.A. 22
Kowa Company, Ltd. 23
Pain Therapeutics, Inc. 24
Pfizer Inc. 25
A. Menarini Industrie Farmaceutiche Riunite Srl 26
Acura Pharmaceuticals, Inc. 27
Elite Pharmaceuticals, Inc. 28
INSYS Therapeutics, Inc. 29
Phosphagenics Limited 30
Trevena, Inc. 31
QRxPharma Limited 32
KemPharm, Inc. 33
Relmada Therapeutics, Inc. 34
ChironWells GmbH 35
Moderate Pain - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 47
oxycodone ER - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(oxycodone + naltrexone) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
(oxycodone hydrochloride + naltrexone hydrochloride) Extended Release - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
K-103IP - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(morphine + oxycodone) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
benzhydrocodone hydrochloride - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
morphine sulfate ER - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NKTR-181 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
(celecoxib + tramadol hydrochloride) - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
oxymorphone hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PTI-202 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PTI-721 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
oxycodone ER - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
levorphanol tartrate ER - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
HS-731 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
TRV-734 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NKTR-194 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
buprenorphine hydrochloride ER - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
HS-731 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ELS-130 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
buprenorphine hydrochloride - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ketorolac tromethamine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
(oxycodone + acetaminophen) - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
hydromorphone IR - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
morphine sulfate IR - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
oxymorphone IR - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
tramadol hydrochloride IR - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
methadone IR - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Moderate Pain - Recent Pipeline Updates 83
Moderate Pain - Dormant Projects 95
Moderate Pain - Discontinued Products 96
Moderate Pain - Product Development Milestones 97
Featured News & Press Releases 97
Mar 04, 2014: KemPharm Expands Global Intellectual Property Estate for KP201 97
Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-001 97
Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-002 for Moderate to Severe Pain 97
Oct 22, 2013: Pfizer Continues Development Program for Remoxy Extended-Release Capsules CII 98
Jun 26, 2013: QRxPharma Updates Moxduo NDA Review 98
Aug 29, 2012: Janssen Receives FDA Approval For Nucynta Extended-release Oral Tablets For Management Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy 99
May 17, 2012: Janssen Presents Phase III Study Results Of NUCYNTA ER Extended-Release Tablets At 31st Annual Scientific Meeting Of American Pain Society 100
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 103
Disclaimer 103

List of Tables

Number of Products under Development for Moderate Pain, H1 2014 10
Number of Products under Development for Moderate Pain - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Development by Companies, H1 2014 (Contd..1) 19
Moderate Pain - Pipeline by Nektar Therapeutics, H1 2014 20
Moderate Pain - Pipeline by Egalet Corporation, H1 2014 21
Moderate Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2014 22
Moderate Pain - Pipeline by Kowa Company, Ltd., H1 2014 23
Moderate Pain - Pipeline by Pain Therapeutics, Inc., H1 2014 24
Moderate Pain - Pipeline by Pfizer Inc., H1 2014 25
Moderate Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 26
Moderate Pain - Pipeline by Acura Pharmaceuticals, Inc., H1 2014 27
Moderate Pain - Pipeline by Elite Pharmaceuticals, Inc., H1 2014 28
Moderate Pain - Pipeline by INSYS Therapeutics, Inc., H1 2014 29
Moderate Pain - Pipeline by Phosphagenics Limited, H1 2014 30
Moderate Pain - Pipeline by Trevena, Inc., H1 2014 31
Moderate Pain - Pipeline by QRxPharma Limited, H1 2014 32
Moderate Pain - Pipeline by KemPharm, Inc., H1 2014 33
Moderate Pain - Pipeline by Relmada Therapeutics, Inc., H1 2014 34
Moderate Pain - Pipeline by ChironWells GmbH, H1 2014 35
Assessment by Monotherapy Products, H1 2014 36
Assessment by Combination Products, H1 2014 37
Number of Products by Stage and Target, H1 2014 40
Number of Products by Stage and Mechanism of Action, H1 2014 43
Number of Products by Stage and Route of Administration, H1 2014 45
Number of Products by Stage and Molecule Type, H1 2014 46
Moderate Pain Therapeutics - Recent Pipeline Updates, H1 2014 83
Moderate Pain - Dormant Projects, H1 2014 95
Moderate Pain - Discontinued Products, H1 2014 96

List of Figures

Number of Products under Development for Moderate Pain, H1 2014 10
Number of Products under Development for Moderate Pain - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Products, H1 2014 17
Assessment by Monotherapy Products, H1 2014 36
Assessment by Combination Products, H1 2014 37
Number of Products by Top 10 Target, H1 2014 38
Number of Products by Stage and Top 10 Target, H1 2014 39
Number of Products by Top 10 Mechanism of Action, H1 2014 41
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 42
Number of Products by Top 10 Route of Administration, H1 2014 44
Number of Products by Stage and Top 10 Route of Administration, H1 2014 45
Number of Products by Stage and Top 10 Molecule Type, H1 2014 46

Companies Mentioned

Nektar Therapeutics
Egalet Corporation
Laboratorios Del Dr. Esteve S.A.
Kowa Company, Ltd.
Pain Therapeutics, Inc.
Pfizer Inc.
A. Menarini Industrie Farmaceutiche Riunite Srl
Acura Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc.
INSYS Therapeutics, Inc.
Phosphagenics Limited
Trevena, Inc.
QRxPharma Limited
KemPharm, Inc.
Relmada Therapeutics, Inc.
ChironWells GmbH

Read the full report:
Moderate Pain - Pipeline Review, H1 2014

http://www.reportbuyer.com/pharma_healthcare/treatments/moderate_pain_pipeline_review_h1_2013.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer



RELATED LINKS
http://www.reportbuyer.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.